Veracyte (NASDAQ:VCYT) CEO Sells $6,919,116.12 in Stock

Posted by Brenda Bartman on Jun 7th, 2026

Veracyte, Inc. (NASDAQ:VCYT – Get Free Report) CEO Marc Stapley sold 138,051 shares of the stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $50.12, for a total value of $6,919,116.12. Following the completion of the sale, the chief executive officer owned 440,494 shares of the company’s stock, valued at approximately $22,077,559.28. This represents a 23.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Veracyte Trading Down 2.4%

Shares of NASDAQ VCYT opened at $48.73 on Friday. Veracyte, Inc. has a 12-month low of $22.61 and a 12-month high of $50.71. The company has a market cap of $3.89 billion, a P/E ratio of 44.71 and a beta of 1.98. The stock has a fifty day moving average price of $37.80 and a 200 day moving average price of $39.08.

Veracyte (NASDAQ:VCYT – Get Free Report) last announced its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.18. Veracyte had a return on equity of 9.07% and a net margin of 16.25%.The firm had revenue of $139.07 million during the quarter, compared to the consensus estimate of $130.36 million. During the same period in the prior year, the firm earned $0.31 EPS. The firm’s quarterly revenue was up 21.5% compared to the same quarter last year. On average, sell-side analysts forecast that Veracyte, Inc. will post 1.29 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on VCYT. Needham & Company LLC upped their price objective on shares of Veracyte from $48.00 to $57.00 and gave the company a “buy” rating in a research report on Monday, June 1st. Wolfe Research began coverage on shares of Veracyte in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $55.00 price objective for the company. Canaccord Genuity Group upped their price objective on shares of Veracyte from $40.00 to $42.00 and gave the company a “hold” rating in a research report on Wednesday, May 6th. Weiss Ratings reissued a “hold (c)” rating on shares of Veracyte in a research report on Friday, March 27th. Finally, Morgan Stanley decreased their price objective on shares of Veracyte from $48.00 to $37.00 and set an “underweight” rating for the company in a research report on Thursday, March 5th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $47.57.

Check Out Our Latest Analysis on VCYT

Hedge Funds Weigh In On Veracyte

Several large investors have recently modified their holdings of VCYT. Fuller & Thaler Asset Management Inc. bought a new position in shares of Veracyte during the fourth quarter worth about $58,158,000. Champlain Investment Partners LLC acquired a new stake in Veracyte during the third quarter worth about $40,064,000. Artisan Partners Limited Partnership raised its stake in Veracyte by 16.6% during the third quarter. Artisan Partners Limited Partnership now owns 7,370,467 shares of the biotechnology company’s stock worth $253,028,000 after acquiring an additional 1,048,692 shares during the period. First Trust Advisors LP raised its stake in Veracyte by 64.9% during the first quarter. First Trust Advisors LP now owns 2,117,046 shares of the biotechnology company’s stock worth $68,190,000 after acquiring an additional 833,543 shares during the period. Finally, Squarepoint Ops LLC raised its stake in Veracyte by 770.6% during the second quarter. Squarepoint Ops LLC now owns 897,387 shares of the biotechnology company’s stock worth $24,256,000 after acquiring an additional 794,307 shares during the period.

Trending Headlines about Veracyte

Here are the key news stories impacting Veracyte this week:

Positive Sentiment: Veracyte has stayed sharply higher since its latest earnings report, suggesting investors are still encouraged by the company’s recent beat on both earnings and revenue and its improved growth outlook. Why Is Veracyte (VCYT) Up 18.2% Since Last Earnings Report?
Positive Sentiment: The company also highlighted ASCO findings from its OPTIMA and ENZAMET Phase III trials in breast and prostate cancer, which could support Veracyte’s precision-diagnostics growth story. Veracyte, Inc. (VCYT) Discusses ASCO Findings From OPTIMA and ENZAMET Phase III Trials in Breast and Prostate Cancer – Slideshow

Veracyte Company Profile

(Get Free Report)

Veracyte, Inc is a genomic diagnostics company focused on improving diagnostic accuracy and patient care through advanced molecular testing. Founded in 2008 and headquartered in South San Francisco, California, the company develops and commercializes minimally invasive genomic tests that aid in the diagnosis of thyroid, lung and other diseases. Veracyte’s proprietary platform analyzes gene expression patterns in clinical samples to help physicians make more informed treatment decisions, reducing unnecessary surgeries and improving patient outcomes.

The company’s flagship product, the Afirma Genomic Sequencing Classifier, is designed to assess thyroid nodules with indeterminate cytology, helping clinicians distinguish benign from suspicious nodules.